Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-01 neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer
2020-004844-27Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in muscle-invasive bladder cancer (MIBC) and bladder cancer, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Pathological complete response. Started Jun 2021; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancer
Beyond the preview
Go deeper on 2020-004844-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004844-27.